Biocardia: HC Wainwright Raises Buy PT to $25 from $25

Biocardia: HC Wainwright Raises Buy PT to $25 from $25

BioCardia Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has priced a $6 million public offering. The offering consists of 4.8 million shares of common stock and short-term warrants to purchase up to 4.8 million additional shares, priced at $1.25 per share and accompanying warrant. The warrants will have an exercise price of $1.25 per share, will be exercisable upon issuance, and will expire two years after issuance BioCardia Announces Pricing of Up To $12 Million Public Offering^[1].

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering, which is expected to close on or about September 19, 2025. If the warrants are fully exercised on a cash basis, BioCardia could receive an additional $6 million in gross proceeds, though the company noted there is no assurance this will occur BioCardia Announces Pricing of Up To $12 Million Public Offering^[1].

BioCardia plans to use the net proceeds for working capital and general corporate purposes, including advancing its investigational biotherapeutic candidates and biotherapeutic delivery partnering business BioCardia Announces Pricing of Up To $12 Million Public Offering^[1].

In a separate development, HC Wainwright has raised its buy price target for BioCardia to $25 from $25, reflecting the company's recent financing activities and the potential for future growth BioCardia stock falls after pricing $6 million public offering^[2].